Tonix Pharmaceuticals shares are trading higher after the company announced it submitted an NDA for TNX-102 SL to the FDA for fibromyalgia treatment. The non-opioid analgesic showed significant pain reduction in Phase 3 studies and received fast-track designation.
Portfolio Pulse from Benzinga Newsdesk
Tonix Pharmaceuticals shares rose after the company submitted an NDA for TNX-102 SL to the FDA for fibromyalgia treatment. The drug showed significant pain reduction in Phase 3 studies and received fast-track designation.
October 16, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tonix Pharmaceuticals' stock is up following the submission of an NDA for TNX-102 SL to the FDA. The drug, aimed at treating fibromyalgia, demonstrated significant pain reduction in Phase 3 trials and has fast-track status.
The submission of an NDA is a significant milestone for Tonix Pharmaceuticals, indicating progress towards potential market approval. The positive Phase 3 results and fast-track designation enhance the drug's prospects, likely boosting investor confidence and stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100